Journal of Histochemistry and Cytochemistry, Vol. 51, 625-631, May 2003, Copyright © 2003, The Histochemical Society, Inc.


ARTICLE

Expression of Macrophage Migration Inhibitory Factor in Acute Ischemic Myocardial Injury

Cheuk-Man Yua, Kevin Wing-Hon Laib, Yong-Xiong Chenb, Xiao-Ru Huangc, and Hui Y. Lanc
a Division of Cardiology, Department of Medicine & Therapeutics, The Chinese University of Hong Kong, Hong Kong
b Division of Cardiology, Department of Medicine, Queen Mary Hospital, University of Hong Kong, Hong Kong
c Division of Nephrology, Baylor College of Medicine, Houston, Texas

Correspondence to: Cheuk-Man Yu, Dept. of Medicine & Therapeutics, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong. E-mail: cmyu@cuhk.edu.hk


  Summary
Top
Summary
Introduction
Materials and Methods
Results
Discussion
Literature Cited

Macrophage migration inhibitory factor (MIF) is a key mediator in inflammatory or immune-mediated diseases, although its role in heart diseases is unknown. This study investigated the expression of MIF in the myocardium in the development of acute myocardial infarction (AMI). By use of immunohistochemistry, Western blotting, RT-PCR, and in situ hybridization, the gene and protein expression of MIF in the heart at 6 hr, 1 day, 3 days, 1 week, and 2 weeks after AMI was studied. In both normal and sham-operated rats, MIF mRNA and protein were expressed constitutively at low levels by the myocytes. By contrast, MIF mRNA was rapidly upregulated by the surviving myocytes in the infarcted region and, to a lesser extent, the non-infarcted region, accounting for a sevenfold increase at 6 hr after AMI (p<0.001). This was followed by a fourfold increase in MIF protein expression at day 1 after AMI (p<0.05). Macrophages were found accumulated in the infarcted region, being significant at day 1 (p<0.01) and progressive increased over the 2-week time course (p<0.01) in which MIF was found expressed in these cells. The results indicated that the infiltrating macrophages and myocytes were sources of MIF in the infarcted region. The latter cells became activated and involved in the amplification of inflammatory response in AMI. Therefore, upregulation of myocardial MIF may contribute to macrophage accumulation in the infarcted region and their pro-inflammatory role may participate in the myocyte damage seen in AMI. (J Histochem Cytochem 51:625–631, 2003)

Key Words: macrophage migration, inhibitory factor, macrophages, myocytes, myocardial infarction, gene expression


  Introduction
Top
Summary
Introduction
Materials and Methods
Results
Discussion
Literature Cited

MACROPHAGE MIGRATION INHIBITORY FACTOR (MIF) was originally described as a product of T-cells that inhibits the migration of macrophages in vitro and promotes macrophage accumulation in the skin delayed-type hypersensitivity reaction (David 1966 ). Recent studies have shown that MIF is constitutively expressed by a variety of cells, including monocytes/macrophages, pituitary and adrenal cells, and renal and skin epithelial cells, as well as endothelial cells (Lan et al. 1996 ). In addition, MIF plays a key role in proinflammatory and immune-mediated diseases such as septic shock (Bacher et al. 1997 ; Calandra et al. 1995 ; Bernhagen et al. 1993 ), glomerulonephritis, renal transplant rejection (Lan et al. 1996 , Lan et al. 1997 , Lan et al. 1998 , Lan et al. 2000 ), and arthritis (Leech et al. 1999 ). In these models, upregulation of MIF has been demonstrated to be responsible for the activation and localization of macrophages and T-cells, resulting in tissue damage (Lan et al. 1996 ). In the cardiovascular system, upregulation of MIF has been shown in vascular endothelial cells and smooth muscle cells in atherosclerotic plaque, which was associated with macrophage accumulation and atherosclerotic plaque formation and progression (Lin et al. 2000 ). However, the role of MIF in the heart disease has not been explored.

Recently, we have demonstrated that, in patients with acute myocardial infarction (AMI), MIF levels were significantly elevated and were higher than those in patients with reversible myocardial ischemia (Yu et al. 2001a ). Because the process of myocyte necrosis in AMI involves the induction of an inflammatory response and subsequent infiltration of inflammatory cells (Yu et al. 2001b ), we postulate that MIF, as a key proinflammatory cytokine, may participate in the development of AMI, which was examined in the present study.


  Materials and Methods
Top
Summary
Introduction
Materials and Methods
Results
Discussion
Literature Cited

Induction of AMI in Rats
Left coronary artery occlusion was performed in 12-week male Sprague–Dawley rats as previously described (Fishbein et al. 1978 ; Yu et al. 2001b ). Anesthetized rats were intubated and ventilated, and left thoracotomy was performed at the fourth and fifth ribs. The left anterior descending artery was ligated 2 mm from the origin of the aorta with 6.0 silk. Sham-operated rats underwent the same operation but without ligating the coronary artery. Rats were sacrificed at 6 hr, 1 day, 3 days, 1 week, or 2 weeks after the surgical procedure. The investigation conforms with the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health (NIH Publication No. 85-23, revised 1996).

In Situ Hybridization
A 420-bp Xba I/BamH I fragment of mouse MIF cDNA in the Bluescript SK+ vector (Stratagene; La Jolla, CA), which is highly homologous to the rat sequence (Sakai et al. 1994 ; Lin et al. 2000 ), was used to prepare sense and antisense digoxigenin-11-UTP MIF cRNA probes according to the manufacturer's protocol (Roche; Mannheim, Germany). In situ hybridization was performed on 4-µm formalin-fixed, paraffin-embedded sections by a microwave heating technique (Lan et al. 1995 , Lan et al. 1996 ). Sections of the heart for in situ hybridization underwent morphometric measurement by systematically scanning the regions using a Zeiss Axiophot microscope at a magnification of x200 (Yu et al. 2001b ). Each image was analyzed using hue, saturation, and intensity detection mode of Leica Qwin Image Analyzer (Leica; Wetzlar, Germany) under a standardized brightness and contrast of light source according to the user manual. Mean values of at least 15 fields were taken in each region of the heart.

Immunohistochemistry
Double immunostaining of MIF expression by infiltrating macrophages in infarcted or non-infarcted heart tissues was performed on 4-µm paraffin sections of formalin-fixed heart with a microwave-based, multiple immunoenzymatic staining (Lan et al. 1995 ) using monoclonal anti-MIF (III.D.9 IgG) and mouse monoclonal anti-ED-1 antibodies as previously described (Serotec; Oxford, England) (Lin et al. 2000 ; Yu et al. 2001b ).

Western Blotting Analysis and EIA Detection of Plasma MIF Level
Total cellular protein was extracted by 50 mM Tris-HCl, pH 8, 100 mM NaCl, 1% Triton X-100, 5 mM EDTA, 1 mM PMSF and a mini-complete proteinase inhibitor cocktail (Roche). Western blotting of MIF has been previously described (Lan et al. 1997 ; Lin et al. 2000 ). Positive signals were then visualized by an enhanced chemiluminescence (ECL) detection system (Amersham–Pharmacia; Arlington Heights, IL). Plasma levels of MIF were measured with a ChemiKine Rat/Mouse MIF EIA kit (Chemicon; Temecula, CA).

Reverse Transcription Polymerase Chain Reaction (RT-PCR)
Frozen heart tissue samples were homogenized and RNA was extracted by the acid–phenol–guanidinium–thiocyanate method (Chomczynski and Cantin 1987 ). The expression of MIF, IL-1ß, and TNF-{alpha} mRNA was detected by RT-PCR using TATA-box binding protein (TBP) as an internal control. The primers used were MIF, 5' CCA GGA CCG CAA CTA CAG CAA 3' (forward) and 5' GGG CTC AAG CGA AGG TGG AAC 3' (reverse); IL-1ß, 5' CCT TCT TTT CCT TCA TCT TTG 3' (forward) and 5' ACC GCT TTT CCA TCT TCT TCT 3' (reverse); TNF-{alpha}, 5' CGT CGT AGC AAA CCA CCA AGC 3'; and TBP, 5' ACC CTT CAC CAA TGA CTC CTA TG 3' (forward) and 5' ATG ATG ACT GCA GCA AAT CGC 3' (reverse). PCR was performed at 94C for 45 sec, 58C for 40 sec, and 72C for 45 sec for 29 cycles. Validations of the semiquantitative RT-PCR were performed using normal rat left ventricular cDNA to ensure that there was no interaction between two pairs of primers, and the reaction condition was standardized for different amounts of cDNA (Jonas et al. 1999 ).

Statistical Analysis
The differences in mean value among the various rat groups were analyzed by one-way analysis of variance (ANOVA) with Scheffe's correction or paired sample t-test where appropriate, using a statistical software program (SPSS for Windows, ver. 10.0; SPSS, Chicago, IL). All data were expressed as mean ± SD. A p value <0.05 was considered statistically significant.


  Results
Top
Summary
Introduction
Materials and Methods
Results
Discussion
Literature Cited

The systolic and diastolic blood pressure remained normal and did not differ between sham and AMI animals throughout the experiments (systolic: sham, 113 ± 12 vs 107 ± 13 mmHg, p=NS; diastolic, sham 93 ± 14 vs 88 ± 13 mmHg, p=NS). There was no difference in the body weight between the groups over the 2-week time course (sham 395 ± 48 vs 411 ± 50 g, p=NS).

Myocardial MIF mRNA and Protein Expression in Normal Hearts and Animals with AMI
Weak MIF mRNA and protein were constitutively expressed by myocardium in both normal and sham-operated rats (Fig 1a, Fig 1b, Fig 2a, Fig 2b, Fig 3, and Fig 4). In contrast, by in situ hybridization and RT-PCR, MIF mRNA was markedly expressed by myocytes in the infarcted region, peaking at 6 hr after AMI (p<0.001) (Fig 1c and Fig 3; Table 1). Upregulation of MIF mRNA by myocytes remained high throughout the study period (Fig 1c–1g). In the noninfarcted area, myocardial MIF mRNA was also upregulated (p<0.01), although to a lesser extent compared to the infarcted region (Fig 1h and Fig 3; Table 1). The MIF protein expression in the infarcted region did not show an early peak but increased gradually over the 2-week study period (Fig 2 and Fig 4; Table 1). Meanwhile, ELISA showed that the MIF level in serum was significantly increased at 6 hr (p<0.001) (Table 1). This may reflect a rapid secretion of the stored cytoplasmic MIF from the damaged myocytes after AMI.



View larger version (147K):
[in this window]
[in a new window]
 
Figure 1. MIF mRNA expression demonstrated by in situ hybridization. The MIF mRNA was stained purple. (a) Normal, (b) 1 week sham-operated, (c) 6 hr, (d) 1 day, (e) 3 days, (f) 1 week, and (g) 2 weeks in the infarcted region. Compared to normal and sham-operated rats in which weak MIF mRNA was constitutively expressed, marked MIF mRNA was upregulated by myocytes at 6 hr and by both myocytes and infiltrating macrophages from day 1 to week 2. (h) An example of the noninfarcted region at week 1. MIF mRNA was also expressed constitutively in the myocytes. Original magnification x400.



View larger version (138K):
[in this window]
[in a new window]
 
Figure 2. Double immunostaining of MIF (blue) and macrophages (brown) in hearts with AMI. (a) Normal and (b) 6 hr sham-operated rats show weak MIF expression by myocytes. Note that no macrophages were found. (c) At 6 hr, (d) 1 day, (e) 3 days, (f) 1 week, and (g) 2 weeks after AMI. Note that MIF protein expression was reduced at 6 hr, restored at day 1, and increased expression (*) from 1 week onwards. ED1+ macrophages were localized exclusively within the infarcted areas where MIF was strongly expressed. Note that most macrophages were also expressing MIF (arrowheads) within the lesions. (h) At 6 hr, noninfarcted region, showing that cytoplasmic MIF in myocytes remains high compared to the infarcted region (c). Original magnification x400.



View larger version (23K):
[in this window]
[in a new window]
 
Figure 3. Multiplex RT-PCR demonstrated the MIF mRNA expression in hearts with AMI. TBP was used as an internal control. The relative abundance of MIF mRNA is expressed as the fraction of internal control and is summarized in Table 1. The MIF mRNA levels peaked at 6 hr and then decreased gradually over 2 weeks. The infarcted region in the normal represents sham-operated rats. n=5 per group.



View larger version (12K):
[in this window]
[in a new window]
 
Figure 4. Western blotting analysis of MIF at different time points and regions of hearts with AMI. The MIF protein was detected in normal rat heart at a low level. After AMI, MIF was markedly increased in the noninfarcted septum at 1 day and continues to be expressed over 2 weeks. However, in the infarcted region the MIF level was lower than in the noninfarcted region throughout the study. The densitometric values of MIF protein are expressed as the fraction of recombinant MIF control. Sep, noninfarcted septum; MI, infarcted region. n=5 per group.


 
View this table:
[in this window]
[in a new window]
 
Table 1. Expression of macrophage migration inhibitory factor (MIF) protein and mRNA as well as interleukin-1ß (IL-1ß) and tumor necrosis factor-{alpha} (TNF-{alpha}) gene expression in the infarcted zone (MI) and the noninfarcted septum in rats (n=5–6 in each group)a

Myocardial MIF Expression and Macrophage Accumulation in the Infarcted Region
As shown in Fig 2, there was no macrophage infiltration in the normal, sham-operated, and noninfarcted heart tissues. In contrast, a significant increase in the number of macrophages was seen at day 1 (p<0.05) and continued to increase throughout the experimental time course (p<0.001) (Fig 2d–2g, Table 1). Infiltrating macrophages were localized exclusively within the infarcted region, where strong MIF expression was found.

MIF Expression by Infiltrating Macrophages
Marked upregulation of MIF mRNA and protein was also found in infiltrating macrophages in the infarcted region. As shown in Fig 1, strong MIF mRNA was found in the macrophages in the infarcted region compared to myocytes in the noninfarcted area (Fig 1d–1h). This was further confirmed by double immunostaining, showing that the ED1+ macrophages were co-expressing MIF within the infarct region (Fig 2d–2g, Table 1), indicating that the activated macrophages are also the major source of MIF during AMI. Correlation analysis showed that upregulation of myocardial MIF correlated closely with the number of infiltrating macrophages in the infarcted lesions (r=0.61; p<0.01).

Expression of Interleukin-1ß and Tumor Necrosis Factor-{alpha} in Normal Hearts and Animals with AMI
In the infarcted region, IL-1ß level was significantly elevated by more than ninefold in the first day of AMI (p<0.01) (Table 1). The level decreased very rapidly afterwards and was no different from the control level from 3 days to 2 weeks. A similar, although smaller surge of IL-1ß level was observed in the noninfarcted area on day 1 (p<0.05), which decreased afterwards. For TNF-{alpha} level, it followed a very similar time course of change to that of IL-1ß, becoming elevated by >20-fold on day 1 in the infarcted region (p<0.001) and decreasing rapidly thereafter (Table 1). In the noninfarcted region, similar changes were observed, although to a much lesser extent than that of the infarcted region.


  Discussion
Top
Summary
Introduction
Materials and Methods
Results
Discussion
Literature Cited

This study demonstrated, for the first time, that upregulation of MIF is involved in AMI. In normal heart, the pre-formed MIF was constitutively and weakly expressed by myocytes. After AMI, MIF mRNA was rapidly upregulated in myocytes within hours, preceding the macrophage infiltration in the infarcted region on day 1. The increase in serum MIF level after AMI and loss of cytoplasmic MIF protein in myocytes suggests that MIF may be rapidly secreted from damaged myocytes. Alternatively, ischemic myocytes may not be able to synthesize MIF protein which, in general, is a later process than mRNA synthesis. These may explain a late and smaller peak observed for protein expression in the infarcted region. On the other hand, the elevated serum MIF level may also be a result of systemic response, although it was not observed in patients with unstable angina in a previous study (Yu et al. 2001a ). The early and rapid upregulation and secretion of MIF by myocytes in the infarcted region, followed by an active inflammatory response including abundant macrophage accumulation and activation, indicated that MIF may play a role in augmenting inflammation-mediated myocardial injury in AMI. On the other hand, cytoplasmic MIF protein and mRNA in the noninfarcted region of the myocardium remained high in the early course of AMI. When located in the peri-infarct zone, it may further amplify the inflammatory response in the infarct zone.

Macrophages, which had originally been considered to be the target of MIF action, were identified as one of the major sources of MIF production during AMI, being evident from day 1 onwards. Indeed, almost all infiltrating macrophages expressed MIF in the infarcted region. Macrophage-derived MIF may both initiate and amplify the inflammatory process during AMI by recruiting more macrophages, neutrophils, and T-cells to the site of inflammation by upregulating the adhesion molecules such as ICAM-1 (Huang et al. 2001 ), by mediating the removal of damaged or necrotic myocytes, by promoting the expression of additional proinflammatory mediators, such as inducible nitric oxide synthase (Calandra et al. 1994 , Calandra et al. 1995 ), and consequently contributing to the remodeling process of the infarcted heart. In the current study, increase in gene expression of other inflammatory cytokines was also observed within the first day of AMI, including IL-1ß and TNF-{alpha}. Such changes were more dramatic in the infarcted region, where myocyte damage was obvious after cellular hypoxia.

It has been shown that myocyte damage after AMI is mediated by an inflammation-like response. This was supported by the observation in animal studies that infiltration of inflammatory cells, such as macrophages and neutrophils, in the infarct zone was evident early after AMI (Sun et al. 1994 ; Yu et al. 2001b ). The present study further suggests the role of an inflammatory response in AMI, which is mediated through MIF in the event of irreversible myocardial ischemia. MIF has been shown to be a key cytokine involved in inflammatory and immune diseases, such as septic shock (Bacher et al. 1997 ; Calandra et al. 1995 ; Bernhagen et al. 1993 ), glomerulonephritis (Lan et al. 1996 , Lan et al. 1997 , Lan et al. 1998 , Lan et al. 2000 ), arthritis (Leech et al. 1999 ), delayed-type hypersensitivity reaction (Bloom and Bennett 1966 ), atherosclerosis (Lin et al. 2000 ), and gastric inflammation (Huang et al. 2001 ). Furthermore, increased serum MIF level has been shown to correlate with the onset of AMI in patients (Yu et al. 2001a ). A recent study also observed that plasma MIF level remain elevated 2 weeks after AMI and, importantly its production from the peripheral blood mononuclear cells was increased more than twofold during the same period (Takahashi et al. 2002 ). In cultured rat cardiac myocytes, significant induction of MIF protein was observed after hypoxia, especially for a more prolonged period (Takahashi et al. 2001 ). MIF, which is released rapidly from pre-formed intracellular stores, may well be one of the first secreted products to be detected as a consequence of macrophage activation (Calandra et al. 1995 ). Once released, MIF can stimulate production of tumor necrosis factor-{alpha}, inducible nitric oxide synthase, and cellular activation (Calandra et al. 1994 , Calandra et al. 1995 ). This central regulatory feature of the action of MIF is likely to account for the observation that in vivo MIF immunoneutralization inhibits the expression of various inflammatory mediators in a wide variety of disease models, such as renal disease, gastric ulcer, septic shock, and atherosclerosis (Lan et al. 1997 ; Calandra et al. 2000 ; Lin et al. 2000 ; Huang et al. 2001 ). A similar mechanism may account for the observation in this study that early and rapid upregulation and secretion of MIF may both initiate and perpetuate the inflammatory response during AMI.

In conclusion, MIF is rapidly and markedly upregulated in myocytes during AMI. Upregulation of MIF by myocytes contributes significantly to macrophage accumulation, and further expression of MIF by infiltrating macrophages may perpetuate the inflammatory response, which may augment the extent of ischemia-induced myocyte damage.


  Acknowledgments

Supported by a research grant from CRCG, University of Hong Kong, Hong Kong (HKU7325/99M).

Received for publication May 22, 2002; accepted November 7, 2002.


  Literature Cited
Top
Summary
Introduction
Materials and Methods
Results
Discussion
Literature Cited

Bacher M, Meinhardt A, Lan HY, Mu W, Metz CN, Chesney JA, Calandra T et al. (1997) Migration inhibitory factor expression in experimentally induced endotoxemia. Am J Pathol 150:235-246[Abstract]

Bernhagen J, Calandra T, Mitchell RA, Martin SB, Tracey KJ, Voelter W, Manogue KR et al. (1993) MIF is a pituitary-derived cytokine that potentiates lethal endotoxaemia. Nature 365:756-759[Medline]

Bloom BR, Bennett B (1966) Mechanism of a reaction in vitro associated with delayed-type hypersensitivity. Science 153:80-82[Medline]

Calandra T, Bernhagen J, Metz CN, Spiegel LA, Bacher M, Donnelly T, Cerami A et al. (1995) MIF as a glucocorticoid-induced modulator of cytokine production. Nature 377:68-71[Medline]

Calandra T, Bernhagen J, Mitchell RA, Bucala R (1994) The macrophage is an important and previously unrecognized source of macrophage migration inhibitory factor. J Exp Med 179:1895-1902[Abstract]

Calandra T, Echtenacher B, Roy DL, Pugin J, Metz CN, Hultner L, Heumann D et al. (2000) Protection from septic shock by neutralization of macrophage migration inhibitory factor. Nature Med 6:164-170[Medline]

Chomczynski P, Cantin M (1987) Single-step method of RNA isolation by acid guanidium thiocyanate-phenol-chloroform extraction. Anal Biochem 162:156-159[Medline]

David JR (1966) Delayed hypersensitivity in vitro: its mediation by cell-free substances formed by lymphoid cell-antigen interaction. Proc Natl Acad Sci USA 56:72-77[Medline]

Fishbein MC, Maclean D, Maroko PR (1978) Experimental myocardial infarction in the rat: qualitative and quantitative changes during pathologic evolution. Am J Pathol 90:57-70[Abstract]

Huang XR, Chun HC, Chen YX, Chun B, Wong Y, Fung PC, Metz C et al. (2001) Macrophage migration inhibitory factor is an important mediator in the pathogenesis of gastric inflammation in rats. Gastroenterology 121:619-630[Medline]

Jonas JC, Sharma A, Hasenkamp W, Ilkova H, Patane G, Laybutt R, Bonner–Weir S et al. (1999) Chronic hyperglycemia triggers loss of pancreatic beta cell differentiation in an animal model of diabetes. J Biol Chem 274:14112-14121[Abstract/Free Full Text]

Lan HY, Bacher M, Yang N, Mu W, Metz C, Meinhardt A, Bucala R et al. (1997) The pathogenic role of macrophage migration inhibitory factor in immunologically induced kidney disease in the rat. J Exp Med 185:1455-1465[Abstract/Free Full Text]

Lan HY, Mu W, Nikolic–Paterson DJ, Atkins RC (1995) A novel, simple, reliable, and sensitive method for multiple immunoenzyme staining: use of microwave oven heating to block antibody crossreactivity and retrieve antigens. J Histochem Cytochem 43:97-102[Abstract/Free Full Text]

Lan HY, Mu W, Yang N, Meinhardt A, Ng YY, Bacher M, Atkins RC, Bucala R (1996) De novo renal expression of macrophage migration inhibitory factor during the development of rat crescentic glomerulonephritis. Am J Pathol 149:1119-1127[Abstract]

Lan HY, Yang N, Brown FG, Isbel NM, Mu W, Metz CN, Bacher M et al. (1998) Macrophage migration inhibitory factor expression in human renal allograft rejection. Transplantation 66:1465-1471[Medline]

Lan HY, Yang N, Yu XQ, Mu W, Isbel NM, Metz CN, Bucala R, Atkins RC (2000) Expression of macrophage migration inhibitory factor in human glomerulonephritis. Kidney Int 57:499-509[Medline]

Leech M, Metz C, Hall P, Hutchinson P, Gianis K, Smith M, Weedon H et al. (1999) Macrophage migration inhibitory factor in rheumatoid arthritis: evidence of proinflammatory function and regulation by glucocorticoids. Arthritis Rheum 42:1601-1608[Medline]

Lin SG, Yu XY, Chen YX, Huang XR, Metz C, Bucala R, Lau CP et al. (2000) De novo expression of macrophage migration inhibitory factor in atherogenesis in rabbits. Circ Res 87:1202-1208[Abstract/Free Full Text]

Sakai M, Nishihira J, Hibiya Y, Koyama Y, Nishi S (1994) Glutathione binding rat liver 13k protein is the homologue of the macrophage migration inhibitory factor. Biochem Mol Biol Int 33:439-446[Medline]

Sun Y, Cleutjens JP, Diaz–Arias AA, Weber KT (1994) Cardiac angiotensin converting enzyme and myocardial fibrosis in the rat. Cardiovasc Res 28:1423-1432[Medline]

Takahashi M, Nishihira J, Katsuki T, Kobayashi E, Ikeda U, Shimada K (2002) Elevation of plasma levels of macrophage migration inhibitory factor in patients with acute myocardial infarction. Am J Cardiol 89:248-249[Medline]

Takahashi M, Nishihira J, Shimpo M, Mizue Y, Ueno S, Mano H, Kobayashi E et al. (2001) Macrophage migration inhibitory factor as a redox-sensitive cytokine in cardiac myocytes. Cardiovasc Res 52:438-445[Medline]

Yu CM, Lau CP, Lai KWH, Huang XR, Lan HY (2001a) Elevation of plasma level of macrophage migration inhibitory factor in patients with acute myocardial infarction. Am J Cardiol 88:774-777[Medline]

Yu CM, Tipoe GL, Lai KWH, Lau CP (2001b) Effects of combination of angiotensin converting enzyme inhibitor and angiotensin receptor antagonist on inflammatory cellular infiltration and myocardial interstitial fibrosis after acute myocardial infarction. J Am Coll Cardiol 38:1207-1215[Medline]